The farnesyltransferase inhibitor FTI-277 suppresses the 24-kDa FGF2- induced radioresistance in HeLa cells expressing wild-type RAS

Elizabeth Cohen-Jonathan, Christine Toulas, Isabelle Ader, Sylvia Monteil, Cuider Allal, Jacques Bonnet, Andrew D. Hamilton, Said M. Sebti, Nicolas Daly-Schveitzer, Gilles Favre

Research output: Contribution to journalArticlepeer-review

Abstract

In this paper, we describe the effect of the inhibitor of farnesyltransferase (FTI-277) on radioresistance induced by the 24-kDa isoform of FGF2 in human cells expressing wild-type RAS. Treatment with FTI- 277 (20 μM) for 48 h prior to irradiation led to a significant decrease in survival of radioresistant cells expressing the 24-kDa isoform (HeLa 3A) but had no effect on the survival of control cells (HeLa PINA). The radio- sensitizing effect of FTI-277 is accompanied by a stimulation of postmitotic cell death in HeLa 3A cells and by a reduction in G2/M-phase arrest in both cell types. These results dearly demonstrate that at least one farnesylated protein is involved in the regulation of the radioresistance induced by the 24-kDa isoform of FGF2. Furthermore, the radiation-induced G2/M-phase arrest is also under the control of farnesylated protein. This work also demonstrates that FTase inhibitors may be effective radio-sensitizers of certain human tumors with wild-type RAS.

Original languageEnglish (US)
Pages (from-to)404-411
Number of pages8
JournalRadiation Research
Volume152
Issue number4
DOIs
StatePublished - Oct 1999

ASJC Scopus subject areas

  • Biophysics
  • Radiation
  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'The farnesyltransferase inhibitor FTI-277 suppresses the 24-kDa FGF2- induced radioresistance in HeLa cells expressing wild-type RAS'. Together they form a unique fingerprint.

Cite this